AbstractInsulin resistance is the hallmark of Type 2 Diabetes and is still an unmet
medical need. Insulin resistance lies at the crossroads of non-alcoholic fatty
liver disease, obesity, weight loss and exercise resistance, heart disease,
stroke, depression, and brain health. Insulin resistance is purely nutrition
related, with a typical molecular disease food intake pattern. The insulin
resistant state is accessible by TyG as the appropriate surrogate marker, which
is found to lead the personalized molecular hepatic nutrition system for highly
efficient insulin resistance remission. Treating insulin resistance with a
molecular nutrition-centered approach shifts the treatment paradigm of Type 2
Diabetes from management to cure. This allows remission within five months, with
a high efficiency rate of 85%. With molecular intermittent fasting a
very efficient treatment for prediabetes and metabolic syndrome is possible,
improving the non-alcoholic fatty liver disease (NAFL) state and enabling the
body to lose weight in a sustainable manner.
Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained
Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic
Syndrome
